Last updated: 2026-09-05 04:41:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
20/20 Biolabs, Inc. (AIDX) operates in the SERVICES-TESTING LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $0.59, with a market capitalisation of $8.05M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.40 to $50.00. This page covers its latest market performance, valuation, price trends and company information.
$8.05M | |
$0.59 | |
$50.00 | |
$0.40 | |
$0.61 | |
130.31K | |
-- | |
-- | |
$50.00 | |
$0.40 | |
-- | |
-- |
20/20 Biolabs, Inc. (AIDX) last closed at $0.61 as of 2026-09-04 23:49:00, unchanged from the previous close of $0.61.
During the latest regular trading session, AIDX traded between $0.40 and $50.00, with a volume of 130.31K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, 20/20 Biolabs, Inc. (AIDX) moved from $0.65 to $0.59, representing a decline of 8.62% ($0.06).
The stock traded between $0.59 and $0.63 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 95.16 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.4%
AIDX is currently trading at $0.59, placing it 0.4% of the way from its 52-week low of $0.40 to its 52-week high of $50.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
| Industry | SERVICES-TESTING LABORATORIES |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of 20/20 Biolabs, Inc. (AIDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.